NEW YORK, January 28, 2013 – Paradigm Medical Industries Inc (OTCPINK: PDMI) is currently trading at $0.0001 on a traded volume of 15.0 million shares. Paradigm Medical Industries develops, manufactures, markets and sells ophthalmic diagnostic instrumentation and related accessories.
Will PDMI Move Higher After Today’s Sudden Selling Activities? Don’t Miss The Free Trend Analysis here http://csrnewsdaily.com/c2/?company=PDMI
Signature Devices Inc (OTCPINK: SDVI) augmented 100% to $0.0002 on a traded volume of 13.06 million shares. The Company has Price/Sales ratio of 0.48 and Price/Book ratio of 0.10. So far this year, the stock is up over 100%. Signature Devices creates, develops and manufactures information technologies, including computer systems, software, and electronics products. The Company also publishes software, including video games, and commercial products. Its technologies include a blend of hardware and software for image generation technology.
How Should Investors Trade SDVI After The Recent Momentum, Find Out Here http://csrnewsdaily.com/c2/?company=SDVI
NanoTech Entertainment Inc (OTCPINK: NTEK) among the top gainers and the stock augmented 88.24% to $0.016. The Company has completed the first phase of a plan to buy back shares of its common stock. The program identified two stages, whereby a total 75 million shares would be acquired in phase one and 120 million shares would be acquired in phase two.
Get Free Special Trend Analysis On NTEK Here http://csrnewsdaily.com/c2/?company=NTEK
NeoMedia Technologies Inc (OTCQB: NEOM) jumped up 18.75% to $0.0019 on a traded volume of 35.44 million shares. Earlier, the Company has granted Progressive Insurance, a worldwide, non-exclusive license to NeoMedia's patents related to mobile barcode resolution. NeoMedia Technologies is the pioneer in 2D mobile barcode technology and infrastructure solutions that enable the mobile barcode ecosystem worldwide.
Get Free Special Trend Analysis On NEOM Here http://csrnewsdaily.com/c2/?company=NEOM
Peregrine Pharmaceuticals (NASDAQ: PPHM) slipped 0.92% to $2.05 on a traded volume of 396k shares. Recently, the Company filed SEC Form 4 related to statement of changes in beneficial ownership of securities.
Roth Capital increased the rating of Peregrine Pharmaceuticals from a neutral rating to a buy rating in a research report released. Roth Capital currently has $2.70 price target on the stock. Peregrine Pharmaceuticals Inc is a biopharmaceutical company developing monoclonal antibodies for the treatment and diagnosis of cancer.
Get Free Special Trend Analysis On PPHM Here http://csrnewsdaily.com/c2/?company=PPHM
Csrnewsdaily.com has a finger on the pulse of many sectors including renewable energy, oil, pharma, mining, finance, and healthcare. Our in depth research and analysis of NASDAQ, OTCQBBB, OTCPINK Sheets, and NYSE has yielded considerable gains for our subscribers.
Our to-the-minute reports and alerts coupled with breaking news, analysis, investment strategies, and FREE subscription email services contribute to our role as one of the leading investor relations marketing firms.
The assembled information disseminated by Csrnewsdaily.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Csrnewsdaily.com does expect that investors will buy and sell securities based on information assembled and presented in phd-trading.com. PLEASE always do your own due diligence, and consult your financial advisor.
Pacific Dynasty Consultants Inc.
2637 E Atlantic Blvd #22611 Pompano Beach, FL 33062